Menú Principal

Bibliografia Fibrosis quística

      1. Sánchez D., Ignacio, Pérez H., M. Angélica, Boza C., M. Lina, Lezana S., Viviana, Vila I., M Alejandra, Repetto L., Gabriela, Hodgson B., M. Isabel, & Ríos M., Gloria. Consenso nacional de fibrosis quística. Revista chilena de pediatría, 72(4), 356-380. 2001;
      2. Rios J, Orellana O, Aspillaga M, Avendano I, Largo I, Riveros N. CFTR mutations in Chilean cystic fibrosis patients. Hum Genet. 1994 Sep;94(3):291–4.
      3. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989 Sep 8;245(4922):1059–65.
      4. Repetto L G, Poggi M H, Harris D P, Navarro M H, Sánchez D I, Guiraldes C E, et al. Identificación de mutaciones en el gen CFTR en pacientes chilenos con fibrosis quística. Rev Médica Chile. 2001;129:841–7.
      5. Restrepo CM, Pineda L, Rojas-Martínez A, Gutiérrez CA, Morales A, Gómez Y, et al. CFTR mutations in three Latin American countries. Am J Med Genet. 2000 Apr 10;91(4):277–9.
      6. Genetic testing for cystic fibrosis. NIH Consens Statement. 1997 Apr 14;15(4):1–37.
      7. Ministerio de Salud. Guía clínica. Fibrosis Quística [Internet]. Ministerio de Salud; 2007. Available from: http://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2014/12/Fibrosis-Qu%C3%ADstica.pdf
      8. Ministerio de Salud. Manual metodológico. Desarrollo de guías de práctica clínica [Internet]. 2014. Available from:http://web.minsal.cl/sites/default/files/files/Manual%20metodologico%20GPC%20151014.pdf
      9. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr. 2006 Sep;149(3):362–6.
      10. Yang C, Chilvers M, Montgomery M, Nolan SJ. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2016 Apr 4;4:CD001127.
      11. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001506.
      12. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197.
      13. Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002767.
      14. Smyth AR, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2014 Nov 24;(11):CD001912.
      15. Houston BW, Mills N, Solis-Moya A. Inspiratory muscle training for cystic fibrosis. Cochrane Database Syst Rev. 2013 Nov 21;(11):CD006112.
      16. Radtke T, Nolan SJ, Hebestreit H, Kriemler S. Physical exercise training for cystic fibrosis. Cochrane Database Syst Rev. 2015 Jun 28;(6):CD002768.
      17. Gao Y-H, Guan W-J, Xu G, Tang Y, Gao Y, Lin Z-Y, et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. PloS One. 2014;9(3):e90047.
      18. Doull IJ, Ryley HC, Weller P, Goodchild MC. Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr Pulmonol. 2001 May;31(5):363–6.
      19. Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest. 2007 Oct;132(4):1212–8.
      20. Tepper RS, Eigen H, Stevens J, Angelicchio C, Kisling J, Ambrosius W, et al. Lower respiratory illness in infants and young children with cystic fibrosis: evaluation of treatment with intravenous hydrocortisone. Pediatr Pulmonol. 1997 Jul;24(1):48–51.
      21. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000 Mar 16;342(11):756–62.
      22. Mastella G, Zanolla L, Castellani C, Altieri S, Furnari M, Giglio L, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatol Off J Int Assoc Pancreatol IAP Al. 2001;1(5):531–7.
      23. Siret D, Bretaudeau G, Branger B, Dabadie A, Dagorne M, David V, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol. 2003 May;35(5):342–9.
      24. Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet Lond Engl. 1985 Dec 14;2(8468):1319–21.
      25. Tluczek A, Becker T, Laxova A, Grieve A, Racine Gilles CN, Rock MJ, et al. Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis. Chest. 2011 Jul;140(1):170–7.
      26. Venkata JA, Jones KL. Benefits of newborn screening for cystic fibrosis in Shreveport, Louisiana, Cystic Fibrosis Center. J La State Med Soc Off Organ La State Med Soc. 2011 Dec;163(6):316–9.
      27. Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest. 2006 Jul;130(1):222–6.
      28. Urquhart D, Sell Z, Dhouieb E, Bell G, Oliver S, Black R, et al. Effects of a supervised, outpatient exercise and physiotherapy programme in children with cystic fibrosis. Pediatr Pulmonol. 2012 Dec;47(12):1235–41.
      29. Dornase Alfa for Patients with Cystic Fibrosis: A Review of the Clinical Efficacy and Cost-Effectiveness | CADTH.ca [Internet]. [cited 2017 Jan 17]. Available from: https://www.cadth.ca/dornase-alfa-patients-cystic-fibrosis-review-clinical-efficacy-and-cost-effectiveness
      30. van der Ploeg CPB, van den Akker-van Marle ME, Vernooij-van Langen AMM, Elvers LH, Gille JJP, Verkerk PH, et al. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2015 Mar;14(2):194–202.
      31. Sodium chloride inhalation for the treatment of cystic fibrosis: a review of the clinical evidence, cost-effectiveness and guidelines [Internet]. [Ottawa, Ont.]: Canadian Agency for Drugs and Technologies in Health; 2012 [cited 2017 Jan 17]. Available from: http://myaccess.library.utoronto.ca/login?url=http://site.ebrary.com/lib/utoronto/Top?id=10610634
      32. Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, et al. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. PharmacoEconomics. 2014 Feb;32(2):159–72.
      33. Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ. 2010;13(3):492–9.
      34. Habib A-RR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc. 2015 Mar;12(3):420–8.
      35. Abbott J, Gee L. Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design. Paediatr Drugs. 2003;5(1):41–56.
      36. Mohamed AF, Johnson FR, Balp M-M, Calado F. Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections. The Patient. 2016 Feb;9(1):59–67.
      37. Dentice RL, Elkins MR, Bye PTP. Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. J Physiother. 2012;58(1):33–40.